NEU is a buy recommendation on The Bull
18 Share Tips – 6 September 2021 - The Bull
https://thebull.com.au/18-share-tips-6-september-2021/
NEU is developing drug therapies to treat neurological disorders that emerge in early childhood. Top line results from its phase 3 trial of lead compound trofinetide – for Rett syndrome – are expected in the fourth quarter of 2021. If all goes to plan and trofinetide is approved and launched in the US, the company is forecasting potential revenue of $A111 million in the US alone, plus royalties on net sales, during 2022 and 2023. However, most pharmaceutical companies carry a degree of risk.
Ann: Trofinetide Rett syndrome clinical trial in girls aged 2-5, page-26
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.09 |
Change
0.000(0.00%) |
Mkt cap ! $2.184B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.00 | 3429 | 4 |
View Market Depth
| Last trade - 16.16pm 08/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable